Viewpoint Molecular Targeting, Inc.: Viewpoint Molecular Targeting Presents Positive Preclinical Results of VMT01 at the 2021 American Association for Cancer (AACR) Annual Meeting
- Preclinical study evaluated melanocortin 1 receptor (MC1R) as a potential target for MC1R-targeted therapies for metastatic melanoma, the lead target of VMT01 - - Results indicate that MC1R-targeted
Source: finanznachrichten.de